A Mulitcenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation in Subjects With Chronic Non-Malignant Pain.
Phase of Trial: Phase III
Latest Information Update: 01 Jan 2016
At a glance
- Drugs Methylnaltrexone bromide (Primary)
- Indications Constipation
- Focus Registrational; Therapeutic Use
- Sponsors Salix Pharmaceuticals
- 03 Jun 2015 The EC approved RELISTOR (methylnaltrexone bromide) subcutaneous injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, according to a Valeant Pharmaceuticals International and Progenics Pharmaceuticals media release.
- 27 Apr 2015 The Committee for Medicinal Products for Human Use (CHMP) of the EMA has adopted a positive opinion recommending approval of methylnaltrexone bromide subcutaneous injection (RELISTOR) for the treatment of opioid-induced constipation in adults, according to a Valeant Pharmaceuticals International media release.
- 05 May 2011 New trial record
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History